长期苯二氮䓬类治疗患者的停药与死亡率
本研究采用模拟试验的比较效果研究设计,利用2013年1月1日至2017年12月31日美国商业保险数据库,纳入长期稳定处方苯二氮䓬类的成人患者,按基线阿片暴露分层,比较停药(基线后6个月宽限期内连续31天无苯二氮䓬类处方覆盖)与继续治疗对12个月随访期内死亡及其他不良事件的影响。无阿片暴露组213 011例,停药者1年调整累积死亡发生率为5.5%(95%CI 5.4%–5.8%),较未停药者绝对风险高2.1个百分点(95%CI 1.9–2.3),死亡风险为未停药者的1.6倍(95%CI 1.6–1.7);有阿片暴露组140 565例,停药者1年调整累积死亡发生率为6.3%(95%CI 6.0%–6.6%),绝对风险高2.4个百分点(95%CI 2.2–2.7),死亡风险为1.6倍(95%CI 1.5–1.7)。停药者非致死性过量、自杀未遂或自伤、自杀意念及急诊就诊的累积发生率亦更高。作者认为,广泛推行苯二氮䓬类停药的政策可能存在非预期风险。
要点
- 无阿片暴露的长期苯二氮䓬类患者停药后1年死亡调整累积发生率为5.5%(95%CI 5.4%–5.8%),较未停药者绝对增加2.1个百分点(95%CI 1.9–2.3),死亡风险为1.6倍(95%CI 1.6–1.7)。
- 有阿片暴露者停药后1年死亡调整累积发生率为6.3%(95%CI 6.0%–6.6%),较未停药者绝对增加2.4个百分点(95%CI 2.2–2.7),死亡风险为1.6倍(95%CI 1.5–1.7)。
- 停药者非致死性过量、自杀未遂或自伤、自杀意念及急诊就诊的累积发生率均高于未停药者。
- 作者认为,广泛推行苯二氮䓬类停药的政策可能存在非预期风险。
- 停药定义为基线后6个月宽限期内连续31天无苯二氮䓬类处方覆盖,主要终点为12个月随访期内死亡。
适用人群与场景
- 美国商业保险数据库中2013年1月1日至2017年12月31日长期稳定处方苯二氮䓬类治疗的成人患者。
- 按基线阿片暴露分为无阿片暴露组(213 011例)和有阿片暴露组(140 565例)。
诊断标准与关键阈值
- 停药定义:基线后6个月宽限期内连续31天无苯二氮䓬类处方覆盖。
研究设计与关键结果
- 研究类型:采用模拟试验方法的比较效果研究;数据来源为美国商业保险数据库;时间范围2013年1月1日至2017年12月31日;数据分析时间2022年12月至2023年11月;采用逆概率加权调整基线混杂及因死亡或退保导致的删失;主要分析为意向性治疗分析,次要分析为符合方案分析。
- 无阿片暴露组213 011例(女性136 609例[64.1%];平均[SD]年龄62.2[14.9]岁;亚裔2953例[1.4%]、黑人18 926例[8.9%]、西班牙裔22 734例[10.7%]、白人168 398例[60.2%]);有阿片暴露组140 565例(女性91 811例[65.3%];平均[SD]年龄61.1[13.2]岁;亚裔1319例[0.9%]、黑人15 945例[11.3%]、西班牙裔11 989例[8.5%]、白人111 312例[79.2%])。
- 无阿片暴露组:停药者1年调整累积死亡发生率为5.5%(95%CI 5.4%–5.8%),较未停药者绝对风险高2.1个百分点(95%CI 1.9–2.3),死亡风险为未停药者的1.6倍(95%CI 1.6–1.7)。
- 有阿片暴露组:停药者1年调整累积死亡发生率为6.3%(95%CI 6.0%–6.6%),较未停药者绝对风险高2.4个百分点(95%CI 2.2–2.7),死亡风险为未停药者的1.6倍(95%CI 1.5–1.7)。
- 停药者非致死性过量、自杀未遂或自伤、自杀意念及急诊就诊的累积发生率亦更高。
证据类型、等级与局限
- 证据类型:采用模拟试验方法的比较效果研究(基于美国商业保险数据库)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在长期稳定处方苯二氮䓬类的患者中(无论有无近期处方阿片暴露),停药与继续治疗相比,危害风险的绝对增加幅度较小。
- 作者认为,广泛推行苯二氮䓬类停药的政策可能存在非预期风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: There is interest in reducing long-term benzodiazepine prescribing given harms associated with use, but the cumulative risks or benefits of discontinuation are unknown.
OBJECTIVE: To identify the association of benzodiazepine discontinuation with mortality and other adverse events among patients prescribed stable long-term benzodiazepine therapy, stratified by baseline opioid exposure.
DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness study with a trial emulation approach included data from a US commercial insurance database between January 1, 2013, and December 31, 2017. Eligible participants were adults with stable long-term benzodiazepine prescription treatment. Data were analyzed between December 2022 and November 2023.
EXPOSURE: Benzodiazepine discontinuation, defined as no benzodiazepine prescription coverage for 31 consecutive days identified during a 6-month grace period after baseline.
MAIN OUTCOME AND MEASURES: Mortality during 12 months of follow-up; secondary outcomes included nonfatal overdose, suicide attempt or self-inflicted injury, suicidal ideation, and emergency department use, identified in medical claims. Inverse probability weighting was used to adjust for baseline confounders that potentially affected treatment assignment and censoring due to death or disenrollment. Primary analysis used an intention-to-treat approach; a secondary per-protocol analysis estimated associations after accounting for nonadherence. Analyses were stratified by opioid use.
RESULTS: The study included 213 011 (136 609 female [64.1%]; mean [SD] age, 62.2 [14.9] years; 2953 Asian [1.4%], 18 926 Black [8.9%], 22 734 Hispanic [10.7%], and 168 398 White [60.2%]) and 140 565 (91 811 female [65.3%]; mean [SD] age, 61.1 [13.2] years; 1319 Asian [0.9%], 15 945 Black [11.3%], 11 989 Hispanic [8.5%], and 111 312 White [79.2%]) patients with stable long-term benzodiazepine use without and with opioid exposure, respectively. Among the nonopioid exposed, the adjusted cumulative incidence of death after 1 year was 5.5% (95% CI, 5.4%-5.8%) for discontinuers, an absolute risk difference of 2.1 percentage points (95% CI, 1.9-2.3 percentage points) higher than for nondiscontinuers. The mortality risk was 1.6 (95% CI, 1.6-1.7) times that of nondiscontinuers. Among those with opioid exposure, the adjusted cumulative incidence of death was 6.3% (95% CI, 6.0%-6.6%) for discontinuers, an absolute risk difference of 2.4 percentage points (95% CI, 2.2-2.7 percentage points) higher than for nondiscontinuers and a mortality risk 1.6 (95% CI, 1.5-1.7) times that of nondiscontinuers. Cumulative incidence of secondary outcomes was also higher among discontinuers.
CONCLUSIONS AND RELEVANCE: This study identifies small absolute increases in risk of harms among patients with stable long-term prescription benzodiazepine treatment who appear to discontinue relative to continuing treatment, including those with and without recent prescription opioid exposure. Policy broadly promoting benzodiazepine discontinuation may have unintended risks.
参考来源
- Maust DT, Petzold K, Strominger J, et al. Benzodiazepine Discontinuation and Mortality Among Patients Receiving Long-Term Benzodiazepine Therapy. JAMA Netw Open. 2023. PMID: 38117495. doi:10.1001/jamanetworkopen.2023.48557
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。